Haemoctin (Human Coagulation Factor Viii)

Haemoctin is a prescription intravenous product containing human coagulation factor VIII as its active ingredient. It is supplied as a sterile injectable solution and is used in the European market to replace deficient factor VIII in patients with bleeding disorders.

Haemoctin is indicated for the management of conditions where factor VIII deficiency leads to impaired clot formation. It is used in both congenital and acquired forms of the disorder and may be administered before surgical or invasive procedures.

- Treatment of hemophilia A (congenital factor VIII deficiency) - Management of acquired hemophilia A - Prophylactic therapy prior to surgery or invasive procedures in patients with factor VIII deficiency - On‑demand treatment of bleeding episodes in patients with hemophilia A - Long‑term prophylaxis to reduce the frequency of bleeding episodes in severe hemophilia A

Adverse reactions to Haemoctin can vary in frequency and severity. Common side effects are usually mild and transient, while serious events are less frequent but require medical attention.

Common: - Headache - Fever or chills - Nausea or vomiting - Local infusion site reactions (pain, erythema) - Transient rise in liver enzymes

Serious: - Development of inhibitors (antibodies) against factor VIII - Anaphylactic or severe allergic reactions - Thromboembolic events (deep vein thrombosis, pulmonary embolism) - Hemolysis or renal impairment in rare cases

Before using Haemoctin, healthcare providers should consider several safety aspects to minimize risks. Individual patient factors and medical history influence the decision to initiate therapy.

- Assess for a history of inhibitors to factor VIII before starting treatment - Monitor for signs of allergic reactions during and after infusion - Evaluate renal and hepatic function periodically during long‑term therapy - Use caution in patients with a personal or family history of thrombosis - Adjust dosing in pediatric patients according to weight and clinical response - Counsel patients on the importance of reporting any unexpected bleeding or swelling

Haemoctin may interact with other medications that affect coagulation or immune response. Awareness of these interactions helps optimize safety and efficacy.

Avoid: - Concomitant use of other clotting factor concentrates without specialist guidance - High‑dose pro‑coagulant agents (e.g., activated prothrombin complex concentrates) unless clinically indicated

Use with caution: - Immunosuppressive drugs that may alter inhibitor development (e.g., rituximab) - Antifibrinolytic agents (e.g., tranexamic acid) – monitor for thrombotic risk - Vaccines administered shortly before or after infusion – observe for immune reactions - Antibiotics known to cause hypersensitivity reactions in susceptible individuals